Related Experiment Video

Updated: Jul 18, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.9K

Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis

Ahmed E Ali1,2, Muhammad Sabry Mazroua2,3, Mariam ElSaban2,4

  • 1Mansoura Specialized Hospital, Mansoura, Egypt.

Global Heart
|August 28, 2023
PubMed

Insights

Dapagliflozin significantly reduces mortality and hospitalizations in heart failure patients. This sodium-glucose cotransporter-2 inhibitor offers promising cardiovascular benefits.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) is a leading cause of global mortality and hospital admissions.
  • Sodium-glucose cotransporter-2 (SGLT2) inhibitors, like dapagliflozin, are emerging as treatments with cardiovascular benefits.
  • This study systematically reviews dapagliflozin's impact on heart failure outcomes.

Approach:

  • A systematic review and meta-analysis of randomized controlled trials.
  • Searched major databases (PubMed, Scopus, ScienceDirect) for studies from January 2017 to September 2022.
  • Included 9 eligible studies with 14,032 patients, analyzing all-cause mortality, HF hospitalization, and cardiovascular death.

Key Points:

  • Dapagliflozin significantly reduced all-cause mortality (RR = 0.89, P = 0.006).
  • Hospitalization due to heart failure was significantly decreased (RR = 0.76, P < 0.00001).
  • Cardiovascular death risk was also lowered (RR = 0.87, P = 0.01), with no significant heterogeneity observed.

Conclusions:

  • Dapagliflozin demonstrates efficacy in reducing mortality and heart failure hospitalizations.
  • The drug benefits a broad spectrum of heart failure patients.
  • SGLT2 inhibitors represent a valuable therapeutic option for managing heart failure.
Abstract

Keywords:
DapagliflozinDiabetes MellitusForxigaHeart failureSGLT2-inhibitors

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.5K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

826

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
15